Journal of Gastrointestinal Surgery

, Volume 17, Issue 12, pp 2092–2098

CA125 is Superior to CA19-9 in Predicting the Resectability of Pancreatic Cancer

  • Guopei Luo
  • Zhiwen Xiao
  • Jiang Long
  • Zuqiang Liu
  • Liang Liu
  • Chen Liu
  • Jin Xu
  • Quanxing Ni
  • Xianjun Yu
Original Article

DOI: 10.1007/s11605-013-2389-9

Cite this article as:
Luo, G., Xiao, Z., Long, J. et al. J Gastrointest Surg (2013) 17: 2092. doi:10.1007/s11605-013-2389-9

Abstract

Background

Although carbohydrate antigen 19-9 (CA19-9) has been reported as a biomarker to predict the resectability of pancreatic cancer, several limitations have restricted its clinical use.

Methods

The potential of several serum tumor markers (CA19-9, CA125, CA50, CA242, CA724, carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP)) to predict the resectability of pancreatic cancer was evaluated by receiver operating characteristic (ROC) analysis in a series of 212 patients with proven pancreatic cancer.

Results

Compared with other tumor markers including CA19-9, CA125 has a superior predictive value (CA19-9, ROC area 0.66, cutoff value 289.40 U/mL; CA125, ROC area 0.81, cutoff value 19.70 U/mL). In addition, for patients with unresectable diseases misjudged by CT as resectable, the percentage of CA125 over selected cutoff value was higher than that of CA19-9 (CA19-9, 70.27 %; CA125, 81.08 %).

Conclusion

CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. Aberrant high levels of CA125 may indicate unresectable pancreatic cancer.

Keywords

Pancreatic cancer Tumor marker Resectability CA19-9 CA125 

Copyright information

© The Society for Surgery of the Alimentary Tract 2013

Authors and Affiliations

  • Guopei Luo
    • 1
    • 2
    • 3
  • Zhiwen Xiao
    • 1
    • 2
    • 3
  • Jiang Long
    • 1
    • 2
    • 3
  • Zuqiang Liu
    • 1
    • 2
    • 3
  • Liang Liu
    • 1
    • 2
    • 3
  • Chen Liu
    • 1
    • 2
    • 3
  • Jin Xu
    • 1
    • 2
    • 3
  • Quanxing Ni
    • 1
    • 2
    • 3
  • Xianjun Yu
    • 1
    • 2
    • 3
  1. 1.Pancreatic Cancer InstituteFudan UniversityShanghaiChina
  2. 2.Department of Pancreas & Hepatobiliary Surgery, Shanghai Cancer CenterFudan UniversityShanghaiChina
  3. 3.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations